ANI Pharmaceuticals (ANI Pharmaceuticals) Market Cap : $1,371.3 Mil (As of Apr. 28, 2024)

View and export this data going back to 1999. Start your Free Trial

What is ANI Pharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). ANI Pharmaceuticals's share price for the quarter that ended in Dec. 2023 was $55.14. ANI Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 20.5 Mil. Therefore, ANI Pharmaceuticals's market cap for the quarter that ended in Dec. 2023 was $1,128.5 Mil.

ANI Pharmaceuticals's quarterly market cap increased from Jun. 2023 ($1,092.1 Mil) to Sep. 2023 ($1,184.1 Mil) but then declined from Sep. 2023 ($1,184.1 Mil) to Dec. 2023 ($1,128.5 Mil).

ANI Pharmaceuticals's annual market cap declined from Dec. 2021 ($775.5 Mil) to Dec. 2022 ($703.8 Mil) but then increased from Dec. 2022 ($703.8 Mil) to Dec. 2023 ($1,128.5 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. ANI Pharmaceuticals's Enterprise Value for Today is $1,460.7 Mil.

ANI Pharmaceuticals Market Cap Historical Data

The historical data trend for ANI Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ANI Pharmaceuticals Market Cap Chart

ANI Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Market Cap

Get a 7-Day Free Trial

745.57

358.77

775.51

703.80

1,128.54

ANI Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Market Cap	Get a 7-Day Free Trial															703.80	714.66	1,092.07	1,184.09	1,128.54

Competitive Comparison of ANI Pharmaceuticals's Market Cap

For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ANI Pharmaceuticals's Market Cap Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where ANI Pharmaceuticals's Market Cap falls into.

ANI Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

ANI Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )	=	Share Price (A: Dec. 2023 )	*	Shares Outstanding (EOP) (A: Dec. 2023 )
	=	$55.14	*	20.4669
	=	$1,128.5

ANI Pharmaceuticals's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )	=	Share Price (Q: Dec. 2023 )	*	Shares Outstanding (EOP) (Q: Dec. 2023 )
	=	$55.14	*	20.4669
	=	$1,128.5

ANI Pharmaceuticals (NAS:ANIP) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

ANI Pharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of ANI Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

ANI Pharmaceuticals (ANI Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ANI Pharmaceuticals Inc (NAS:ANIP) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

BSFA:Germany

Address

210 Main Street West, Baudette, MN, USA, 56623

Website

https://www.anipharmaceuticals.com

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Executives

Muthusamy Shanmugam	director, officer: HEAD OF R&D, COO-NOVITIUM OPS	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Meredith Cook	officer: SR. VP, GENERAL COUNSEL & SEC.	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Krista Davis	officer: SVP, CHIEF HR OFFICER	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Christopher Mutz	officer: HEAD OF RARE DISEASE	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Chad Gassert	officer: SVP - CORP. DEV. & STRATEGY	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Ori Gutwerg	officer: SVP, GENERICS	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
James G. Marken	officer: Vice President, Operations	210 MAIN STREET WEST, C/O BIOSANTE PHARMACEUTICALS, INC., BAUDETTE MN 56623
Matthew J Leonard	director	7 CUSTOM HOUSE STREET, PORTLAND ME 04101
Meridian Venture Partners Ii Lp	10 percent owner
Nikhil Lalwani	director, officer: PRESIDENT & CEO	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET, BAUDETTE MN 56623
Antonio R Pera	director	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET, BAUDETTE MN 56623
Stephen P. Carey	officer: Vice President and CFO	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Renee P Tannenbaum	director	9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Jeanne Thoma	director	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Patrick D Walsh	director	14282 FRANKLIN AVE., TUSTIN CA 92780